Nivolumab and immune‐mediated colitis

Nivolumab is associated with a number of immune‐regulated adverse events, including immune‐mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Heather, Brennan, Paul, Groome, Maximillian, Walsh, Shaun, Carey, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452469/
https://www.ncbi.nlm.nih.gov/pubmed/30997054
http://dx.doi.org/10.1002/ccr3.2027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452469/
https://www.ncbi.nlm.nih.gov/pubmed/30997054
http://dx.doi.org/10.1002/ccr3.2027

Ejemplares similares